In Parkinson's disease, affective and chronic fatigue syndrome symptoms are associated with neuronal damage markers.

BackgroundParkinsons disease (PD) is frequently accompanied by mood and chronic fatigue syndrome (CFS) symptoms. It is unknown whether immune activation and insulin resistance (IR) or brain injuries impacts the severity of affective and CFS symptoms due to PD. AimsTo examine whether immune, IR, and/or brain injury biomarkers determine affective and CFS symptoms due to PD. MethodsUsing a case (70 PD patients) control (60 healthy controls) study design, we assessed affective and CFS symptoms, measured the peripheral immune-inflammatory response system (IRS) using interleukin-6 (IL-6), IL-10, zinc, and calcium levels, the Homeostasis Model Assessment 2 insulin resistance (HOMA2IR) index, and serum brain injury markers including S100 calcium-binding protein B (S100B), neuron-specific enolase (NSE), phosphorylated tau217 (pTau217), and glial fibrillary acidic protein (GFAP). ResultsPD patients showed increased affective and CFS scores, IRS activation, HOMA2IR, NSE, GFAP, pTau217, and S100B levels as compared to controls. A large part (52.5%) of the variance in the mood+CFS score was explained by the regression on NSE, S100B, HOMA2IR index, interleukin-10 (IL-10) (all positively) and calcium (inversely). The HOMA2IR and IRS indices were significantly associated with all 4 brain injury biomarkers. A large part of the variance in the latter markers (37.0%) was explained by the cumulative effects of the IRS and HOMA2IR indices. DiscussionRS activation and IR in patients with PD contribute to damage to glial cell projections and type III intermediate filament, which in turn contribute to affective and CFS symptoms.